Appl. No. 10/006,069 Amdt. dated May 8, 2003 Reply to Office Action of April 9, 2003

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-20 (withdrawn)

Claim 21 (currently amended) A nucleic acid encoding a polypeptide, wherein the polypeptide comprises a zinc finger according to claim 1 protein that binds to a target site, wherein the target site has a nucleotide sequence as specified in Table 3 or Table 4:

Claim 22 (currently amended) A nucleic acid encoding a polypeptide according to claim 21, wherein the polypeptide comprises a zinc finger protein according to elaim 4 target site is one of the nucleotide sequences in a row of Table 3 and positions –1 to +6 in each zinc finger are occupied by first, second and third segments of seven contiguous amino acids as specified in a row of Table 3, and wherein at least one zinc finger is a C2H2 zinc finger.

Claim 23 (currently amended) A nucleic acid encoding a polypeptide according to claim 21, wherein the polypeptide comprises a zinc finger protein according to elaim 7 zinc finger protein comprises six zinc fingers, and positions –1 to +6 in each of the six zinc fingers are occupied by a segment of seven contiguous amino acids as specified in a row of Table 4, and wherein at least one zinc finger is a C2H2 zinc finger.

Claim 24 (currently amended) A nucleic acid encoding a polypeptide according to claim 21, wherein the polypeptide comprises a zinc finger protein according to claim 9 zinc finger protein is a fusion protein comprising a regulatory domain.

Claims 25-85 (withdrawn)

Claim 86 (currently amended) A pharmaceutical composition comprising

Appl. No. 10/006,069 Amdt. dated May 8, 2003 Reply to Office Action of April 9, 2003

(a) a nucleic acid according to claim 14 claim 21 operably linked to a regulatory sequence, and a pharmaceutically acceptable carrier or diluent, wherein the regulatory sequence allows for expression of the nucleic acid in a cell; and

(b) a pharmaceutically acceptable carrier or diluent.

Claim 87 (original) The pharmaceutical composition according to claim 86, wherein the nucleic acid is contained in an expression vector.

Claim 88 (original) The pharmaceutical composition according to claim 87, wherein the expression vector is a viral expression vector.

Claim 89 (original) The pharmaceutical composition according to claim 88, wherein the expression vector is selected from the group consisting of a retroviral expression vector, an adenoviral expression vector, and an AAV expression vector.

Claims 90-98 (withdrawn)